Financials Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-03 pm EST			5-day change	1st Jan Change
16.23 ^USD	-2.76%		+0.37%	-15.20%

Nov. 20	Myriad Genetics, Inc. Announces Updates to Its Agreement with Illumina Inc	CI
Nov. 19	Sintx Technologies, Inc. Appoints Gregg R. Honigblum as Chief Strategy Officer	CI

Projected Income Statement: Myriad Genetics, Inc.

income-statement-evolution-chart MYRIAD-GENETICS-INC

Fiscal Period: Dezember	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	851.1	557	690.6	678.4	753.2	840.8	885.4	974.8
Change	-	-34.56%	23.99%	-1.77%	11.03%	11.62%	5.32%	10.1%
EBITDA ¹	218.2	-	71.9	-21	-6.3	36.28	36.89	72.58
Change	-	-100%	-	-	-70%	-	1.68%	96.73%
EBIT ¹	145.2	-77.9	9.1	-32.8	-25.5	19.68	14.7	52.96
Change	-	-	-	-	-22.26%	-	-25.29%	260.29%
Interest Paid ¹	-12	-7.8	-5.9	-3.2	-2.9	-1.917	-2	-1.15
Earnings before Tax (EBT) ¹	-	-	-57.1	-140.6	-262.2	-104.8	-57.82	-9.92
Change	-	-	-	146.23%	86.49%	60.02%	44.85%	82.84%
Net income ¹	4.6	-	-27.2	-112	-263.3	-105.6	-72.04	-11.72
Change	-	-100%	-	311.76%	135.09%	59.89%	31.78%	83.73%
Announcement Date	8/13/19	2/23/21	2/24/22	2/28/23	2/27/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2019 Q4	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3
Net sales ¹	215.4	154.6	173.1	189.4	167.3	160.8	164.9	179.3	156.4	177.8	181.2	183.5	191.9	196.6	202.2	211.5	213.3	213.6	213.4	222.2	221.7	228.2	230.3	239.6	242.6
Change	-	-28.23%	11.97%	9.42%	-11.67%	-3.89%	2.55%	8.73%	-12.77%	13.68%	1.91%	1.27%	4.58%	2.45%	2.85%	4.6%	0.85%	0.12%	-0.06%	4.09%	-0.22%	2.95%	0.93%	4.03%	1.26%
EBITDA ¹	51.5	-	15.1	30.4	12.8	13.4	10.2	7.3	-17.6	-10.7	-20.5	-4.2	1.2	10.1	4.4	11.9	14.1	7.38	6.468	10.91	10.09	11.98	-	-	-
Change	-	-100%	-	101.32%	-57.89%	4.69%	-23.88%	-28.43%	-	-39.2%	91.59%	-79.51%	-	741.67%	-56.44%	170.45%	18.49%	-47.66%	-12.35%	68.73%	-7.59%	18.76%	-100%	-	-
EBIT ¹	33.2	-11.3	-3.3	13.5	-1.4	0.1	-2.8	4.5	-20.6	-13.9	-21.9	-6.8	-2.2	5.7	-0.6	7.4	9.5	3.334	1.503	6.132	6.102	7.297	-	-	-
Change	-	-	-70.8%	-	-	-	-	-	-	-32.52%	57.55%	-68.95%	-67.65%	-	-	-	28.38%	-64.9%	-54.93%	308.07%	-0.48%	19.59%	-100%	-	-
Charge d'intérêts ¹	-3.2	-2.6	-2.8	-1.8	-0.9	-0.4	-0.9	-0.6	-0.8	-0.9	-0.5	-0.5	-1	-0.9	-0.5	-0.8	-0.8	-0.5	-0.5	-0.5	-0.5	-0.5	-0.1	-0.1	-0.1
Earnings before Tax (EBT) ¹	-7.7	-	-49.6	-3.8	39.8	-43.5	-26.4	-17.9	-44.2	-52.1	-52.6	-116.1	-61.2	-32.3	-25.9	-37.2	-21.2	-20.53	-19.16	-15.33	-12.7	-10.63	-6.624	-2.856	-2.086
Change	-	-100%	-	-92.34%	-	-	-39.31%	-32.2%	146.93%	17.87%	0.96%	120.72%	-47.29%	-47.22%	-19.81%	43.63%	-43.01%	3.15%	6.7%	19.99%	17.13%	16.3%	37.69%	56.89%	26.98%
Net income ¹	-4.2	-	-39.5	-4.7	24.6	-7.6	-20.5	-14.1	-35.1	-42.3	-54.7	-116.1	-61.3	-31.2	-26	-36.7	-22.1	-20.8	-19.22	-15.21	-13.07	-11.02	-6.824	-2.906	-2.786
Change	-	-100%	-	-88.1%	-	-	169.74%	-31.22%	148.94%	20.51%	29.31%	112.25%	-47.2%	-49.1%	-16.67%	41.15%	-39.78%	5.89%	7.58%	20.88%	14.07%	15.65%	38.09%	57.42%	4.15%
Announcement Date	8/13/19	2/23/21	5/3/21	8/3/21	11/2/21	2/24/22	5/5/22	8/4/22	11/1/22	2/28/23	5/3/23	8/3/23	11/6/23	2/27/24	5/7/24	8/6/24	11/7/24	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Myriad Genetics, Inc.

balance-sheet-analysis-chart MYRIAD-GENETICS-INC

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	96.6	108	-340	-115	-102	-73.1	-87.1	-121
Change	-	11.8%	-414.81%	-133.82%	-188.7%	-171.39%	-219.15%	-238.92%
Announcement Date	8/13/19	2/23/21	2/24/22	2/28/23	2/27/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Myriad Genetics, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	8.6	10.2	18	45.3	63.2	23	22.3	22
Change	-	18.6%	76.47%	151.67%	39.51%	-63.61%	-3.04%	-1.35%
Free Cash Flow (FCF) ¹	75.1	-64.6	162.2	-151.6	-174.1	3	9	24
Change	-	-186.02%	-351.08%	-193.46%	14.84%	-101.72%	200%	166.67%
Announcement Date	8/13/19	2/23/21	2/24/22	2/28/23	2/27/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Myriad Genetics, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	25.64%	-	10.41%	-3.1%	-0.84%	4.32%	4.17%	7.44%
EBIT Margin (%)	17.06%	-13.99%	1.32%	-4.83%	-3.39%	2.34%	1.66%	5.43%
EBT Margin (%)	-	-	-8.27%	-20.73%	-34.81%	-12.47%	-6.53%	-1.02%
Net margin (%)	0.54%	-	-3.94%	-16.51%	-34.96%	-12.56%	-8.14%	-1.2%
FCF margin (%)	8.82%	-11.6%	23.49%	-22.35%	-23.11%	0.36%	1.02%	2.46%
FCF / Net Income (%)	1,632.61%	-	-596.32%	135.36%	66.12%	-2.84%	-12.49%	-204.79%
Profitability
ROA	9.27%	-3.57%	0.1%	-1.92%	-1.93%	1.08%	0.71%	3.1%
ROE	12.35%	-5.6%	0.15%	-12.08%	-2.71%	1.41%	1.17%	5.46%
Financial Health
Leverage (Debt/EBITDA)	0.44x	-	-	-	-	-	-	-
Debt / Free cash flow	1.29x	-1.67x	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	1.01%	1.83%	2.61%	6.68%	8.39%	2.74%	2.52%	2.26%
CAPEX / EBITDA (%)	3.94%	-	25.03%	-215.71%	-1,003.17%	63.4%	60.45%	30.31%
CAPEX / FCF (%)	11.45%	-15.79%	11.1%	-29.88%	-36.3%	766.67%	247.78%	91.67%
Items per share
Cash flow per share ¹	1.101	-	0.2333	-1.319	-1.339	1.974	2.214	-
Change	-	-	-	-665.23%	1.53%	-247.43%	12.16%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	14.81	11.68	12.1	10.91	8.712	7.917	7.616	7.732
Change	-	-21.13%	3.54%	-9.83%	-20.14%	-9.12%	-3.81%	1.53%
EPS ¹	0.06	-3.08	-0.35	-1.39	-3.18	-1.168	-0.7875	-0.125
Change	-	-5,233.33%	-88.64%	297.14%	128.78%	-63.29%	-32.55%	-84.13%
Nbr of stocks (in thousands)	74,389	75,210	79,855	81,034	88,669	91,035	91,035	91,035
Announcement Date	8/13/19	2/23/21	2/24/22	2/28/23	2/27/24	-	-	-